- Jue Sep 04, 2014 12:10 pm
#429077
Hola abro este hilo para informar de el inicio de la locion topica de finasteride, a ver que tal, he decidido suspender la presentacion oral para intentar con la topica a ver que tal, sobretodo en cuanto a tolerabilidad de miorganismo y en cuanto comparacion de secundarios, parece ser que la biodisponibilidad de la formulacion topica es menor por lo que podria provocar menos secundarios, ya os ire contando mi experiencia personal
Mientras aca os dejo un abstract que he sacado de un usuario de Hairlosstalk
This study suggests they are exactly the same in terms of effectiveness and sides
Int J Clin Pharmacol Ther. 2014 Jul 30. [Epub ahead of print]
A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers.
Caserini M, Radicioni M, Leuratti C, Annoni O, Palmieri R.
Abstract
Objective: Finasteride, a selective inhibitor of type 2 5-alpha reductase isoenzyme, inhibits the conversion of testosterone to dihydrotestosterone (DHT) and is indicated in the treatment of male androgenetic alopecia. The study objective was to evaluate a newly developed finasteride 0.25% topical solution in comparison to the marketed finasteride 1 mg tablet, with respect to finasteride pharmacokinetics and suppressive effects on plasma DHT. Methods: 24 healthy men with androgenetic alopecia were randomized in a single center, open-label, parallel-group, exploratory study, and received either multiple scalp applications of the topical solution b.i.d. or oral doses of the reference tablet o.d. for 7 days. Plasma finasteride, testosterone and DHT concentrations were determined. Results: After multiple doses, mean (± SD) finasteride Cmax and AUC00-t corresponded to 0.46 ± 0.28 ng/mL and 6.64 ± 7.50 ng/mL x h for the topical solution and to 6.86 ± 1.78 ng/mL and 57.93 ± 29.38 ng/mL x h for the tablet. Plasma DHT was reduced by ~ 68 - 75% with the topical solution and by ~ 62 - 72% with the tablet. No relevant changes occurred for plasma testosterone with either treatment. No clinically significant adverse events occurred. Conclusions: A strong and similar inhibition of plasma DHT was found after 1 week of treatment with the topical and tablet finasteride ormulations, albeit finasteride plasma exposure was significantly lower with the topical than with the oral product (p < 0.0001).
Basicamente dice que los niveles plasmaticos de finas topico eran menor que la tableta pero que suprimia incluso mas DHT, pero a dosis de 0.25% que corresponderia a 2.5 mg/1ml, la mia es al 0.05% que corresponderia a 0.5mg/1ml
Un saludo
Mientras aca os dejo un abstract que he sacado de un usuario de Hairlosstalk
This study suggests they are exactly the same in terms of effectiveness and sides
Int J Clin Pharmacol Ther. 2014 Jul 30. [Epub ahead of print]
A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers.
Caserini M, Radicioni M, Leuratti C, Annoni O, Palmieri R.
Abstract
Objective: Finasteride, a selective inhibitor of type 2 5-alpha reductase isoenzyme, inhibits the conversion of testosterone to dihydrotestosterone (DHT) and is indicated in the treatment of male androgenetic alopecia. The study objective was to evaluate a newly developed finasteride 0.25% topical solution in comparison to the marketed finasteride 1 mg tablet, with respect to finasteride pharmacokinetics and suppressive effects on plasma DHT. Methods: 24 healthy men with androgenetic alopecia were randomized in a single center, open-label, parallel-group, exploratory study, and received either multiple scalp applications of the topical solution b.i.d. or oral doses of the reference tablet o.d. for 7 days. Plasma finasteride, testosterone and DHT concentrations were determined. Results: After multiple doses, mean (± SD) finasteride Cmax and AUC00-t corresponded to 0.46 ± 0.28 ng/mL and 6.64 ± 7.50 ng/mL x h for the topical solution and to 6.86 ± 1.78 ng/mL and 57.93 ± 29.38 ng/mL x h for the tablet. Plasma DHT was reduced by ~ 68 - 75% with the topical solution and by ~ 62 - 72% with the tablet. No relevant changes occurred for plasma testosterone with either treatment. No clinically significant adverse events occurred. Conclusions: A strong and similar inhibition of plasma DHT was found after 1 week of treatment with the topical and tablet finasteride ormulations, albeit finasteride plasma exposure was significantly lower with the topical than with the oral product (p < 0.0001).
Basicamente dice que los niveles plasmaticos de finas topico eran menor que la tableta pero que suprimia incluso mas DHT, pero a dosis de 0.25% que corresponderia a 2.5 mg/1ml, la mia es al 0.05% que corresponderia a 0.5mg/1ml
Un saludo
